In this issue of JAMA, Webster and colleagues1 report the results of the Triple Pill vs Usual Care Management for Patients with Mild-to-Moderate Hypertension (TRIUMPH) pragmatic randomized clinical trial that evaluated the efficacy of a low-dose combination pill containing 20 mg of telmisartan, 2.5 mg of amlodipine, and 12.5 mg of chlorthalidone compared with usual care among 700 adults with hypertension in Sri Lanka. The primary outcome was the proportion of patients whose blood pressure (BP) was controlled at 6 months, which was defined as a systolic/diastolic BP of less than 140/90 mm Hg or less than 130/80 mm Hg among patients with diabetes or chronic kidney disease at baseline or newly diagnosed (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2).